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The subject invention relates to a process for artificially producing three-dimensional optic tissue,
and to the optic tissue produced thereby. Optic cells are cultured in a bioreactor at low shear
conditions, forming normal, functional tissue organization and extracellular matrix.
Optic cells, more specifically, cornea cells, are selected and introduced into a cylindrical culture
vessel containing culture media, which vessel rotates about its central horizontal axis. The cells
are cultured in the vessel during horizontal rotation carefully modulated to create low shear
conditions, such that three-dimensional cell growth is achieved.
The novelty of the invention appears to lie in the provision of artificially produced cornea tissue
which promises to provide another alternative to the use of donor tissue for corneal
transplantation. The instant process can be used to prepare corneal tissue from in vitro cultures
of the patient's own corneal cells, or from a well-defined primary culture derived from another
human source, thus avoiding the problems associated with donor tissue, particularly those
associated with the perennial critical shortage.
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ORIGIN OF THE INVENTION
The jointly made invention described herein was made
by employees of the United States Government and may be
manufactured and used by or for the Government of the
United States of _nerica for governmental purposes without
the payment of any royalties thereon or therefor.
The invention described herein was also made by
inventors in the performance of work under a NASA contract
with Krug Life Sciences and a memorandum of understanding
with Tulane University and is subject to the provisions of
Section 305 of the National Aeronautics and Space Act of
1958, Public Law 85-568 (72 Stat. 435; 42 U.S.C. 2457).
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RELATED PATENTS AND APPLICATIONS
The present case is a continuation-in-part of United
States Patent Application Serial Number 08/066,292 filed
May 25, 1993, which is a continuation-in-part of United
States Patent Application Serial Number 07/939,791, filed
September 3, 1992, entitled "Three-Dimensional Coculture
Process" which is a continuing application of Serial Number
07/317,931, filed March 2, 1989, entitled "Three-Dimen-
sional Coculture Process", now U.S. Patent No. 5,153,132,
issued October 6, 1992, which is a continuation-in-part of
Serial No. 317,776, filed March 2, 1989, entitled "Three
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Dimensional Cell and Tissue Assembly Process", now U.S.
Patent No. 5,155,034, issued October 13, 1992, which is a
continuation-in-part of Serial No. 213,588, filed June 30,
1988, now U.S. Patent No. 5,026,650, issued June 25, 1991,
entitled "Horizontally Rotated Cell Culture System with a
Coaxial Tubular Oxygenator" and Serial No. 213,559, filed
June 30, 1988, now Patent No. 4,988,623, issued January 29,
1991, entitled "Rotating Bio-Reactor Cell Culture Ap-
paratus", and Serial No. 625,345, filed December ii, 1990,
now U.S. Patent No. 5,153,131, issued October 6, 1992,
entitled "High Aspect Reactor Vessel and Method of Use",
all of which are specifically incorporated by reference as
if fully set forth herein.
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FIELD OF THE INVENTION
The _ invention relates to the production of three
dimensional tissue from a culture of cells in fluid media.
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BACKGROUND OF THE INVENTION
Optic tissue associated with light transmission and
image focusing for photoreception is formed in almost all
animal life forms. The cornea is exemplary of optic
tissue.
In vivo, the cornea serves to focus light and to form
the anterior wall of the eye. It is composed of transpar-
ent tissue that is on average 0.55 mm thick in the central
region of the cornea and ii mm in diameter in adult humans,
and is organized into six distinct regions lying parallel
to the anterior and posterior surface. The structural
order of these regions gives rise to the transparence of
the cornea. The epithelium is located on the anterior
surface of the cornea and is composed of five to six layers
of cells in humans. The basal layer of the epithelium is
connected via numerous attachment bodies to the basement
membrane, a tightly packed filamentous layer i00 to 300
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thick. On the posterior side of this membrane, lies the
stroma which accounts for nine-tenths of the thickness of
the cornea in most mammals. It is composed primarily of
keratocytes and, to a far lesser degree, leucocytes that
lie between nearly 200 parallel layers of stroma lamellae
that is formed from extracellular matrix. The outermost
anterior portion of the stroma forms the Bowman's zone.
Approximately 12 _m thick, this zone is a cell-free layer
of stroma containing extracellular matrix fibrils felted
together in an irregular manner. The stroma is located
between two membranes, the basement membrane as previously
discussed and Descemet's membrane which is a sheet of
extracellular matrix, 5 to i0 _m thick, bound to the
posterior side of the stroma. This second membrane is
lined by the endothelium, a single layer of cells, that
forms the posterior surface of the cornea. These cells are
characterized by their hexagonal shape, giving the endothe-
lium a mosaic structure. This and other information on
corneal tissue is summarized by Kaufman [Kaufman, H.E.,
McDonald, M.B., Barron, B.A., and Waltman, S.R., The Cornea
(Churchill Livingstone, New York, 1988)].
Within corneal tissue, the extracellular matrix serves
as scaffolding to provide mechanical strength and structur-
al organization. After being synthesized and secreted from
corneal cells, the matrix forms distinct three-dimensional,
lattice-like arrangements in the extracellular space of
corneal tissue [Komai, Y. and Ushiki, T., Invest. Ophthal-
mol. Vis. Sci., 32, 2244 (1991)]. Considering the stroma,
fibrils of extracellular matrix are interwoven to form
dense felt-like sheets in Bowman's layer. At the interface
between the stroma and Descemet's membrane, the matrix
becomes a loose ffbrillar network oriented in various
directions and interlaced. In between these two regions,
the stroma is composed of successively stacked layers of
flat lamella bundles of matrix fibrils.
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There are primarily two classes of macromolecules
present in the extracellular matrix: glycosaminoglycans
(GAG'S) including chondroitin sulfate and dermatan sulfate,
and fibrous proteins such as fibronectin and collagen. The
role of the latter group is mainly structural and adhesive.
For example, fibronectin binds to cells and to other matrix
macromolecules, promoting cell attachment to and subsequent
migration along the matrix [Alberts B., Bray, D., Lewis,
J., Raff, M., Roberts, K., and Watson, J.D., Molecular
Biology of the Cell (Garland Publishing, New York, 1989)].
In the cornea, GAG's regulate spacing between fibrils and
the three-dimensional organization of stroma lamellae
[Hahn, R. A. and Birk, D.E., Development, 115, 383 (1992)].
In addition, they regulate the kinetics of fibril formation
[Birk, D.E. and Lande, M.A., Biochim, Biophys. Acta, 670,
362 (198i) ].
Expression and proper three-dimensional organization
of extracellular matrix is essential for corneal transpar-
ency. When expression or organization is inhibited, the
tissue becomes opaque. This condition occurs in patients
with muscular dystrophy. The disease is characterized by
improper biosynthesis of keratin sulfate, a GAG [Hassell,
J.R., Newsome, D.A., Krachmer, J.H., and Rodrigues, M.,
Proc. Natl. Acad. Sci. U.S.A., 77, 3705 (1980); Nakazawa,
K., Hassell, J.R., Hascall, V.C., Lohmander, L.S., Newsome,
D.A., and Krachmer, J., J. Biol. Chem., 259, 13751 (1984)].
It can also be induced chemically with agents such as 6-D
xyoside [Hahn, R.A. and Birk, D.E., Development, 115, 383
(1992) ].
Corneal transplants are the most frequently performed
human transplant procedure. Since 1961, there have been
more than 421,300 corneal transplantations performed in the
U.S. In 1991 alone, there were 41,300 such transplanta-
tions, more than all other organ transplantations performed
in that year [Eye Bank Association of America, Annual
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Report (Washington, D.C., 1992]. Greater than 90% of
corneal transplant operations successfully restore vision.
The reasons for transplantation are varied. They include
corneal dystrophy which results from, for example, malnu-
trition, dehydration and radiation exposure; keratoconus
which can cause the cornea to rupture if change in corneal
shape is severe; keratitis from viral or microbial sources;
corneal degeneration in the elderly; chemical injury;
physical trauma; transplant rejection; edema which can
result from trauma to the endothelium inhibiting fluid flow
between the cornea and anterior chamber; and corneal
leukoma [Leibowitz, H.M., Corneal Disorders: Clinical
Diagnosis and Management (W.B. Saunders, Philadelphia,
1984; Brightbill, F.S., Corneal Surgery: Theory, Technique,
and Tissue (Mosby-Year Book, St. Louis, 1993)].
The majority of corneal transplantations are performed
with donor tissue. The use of donor tissue results in
several complications, including donor shortage. There are
in excess of 5,000 patients on waiting lists for donor
tissue throughout the U.S. [Eye Bank Association of Ameri-
ca, Annual Report (Washington, D.C., 1992)]. These people
wait between two weeks and two years to obtain suitable
tissue. And when this tissue becomes available, there is
still the possibility of transplant rejection and disease
transfer of }{IV [Salahuddin, S.Z., Palestine, A.G., Heck,
E., Ablashie, D., Luckenbach, M., McCulley, J.P., and
Nussenblatt, R.B., Am. J. Ophthalmol., 104, 149 (1986)],
hepatitis B [Raber, I.M. and Friedman, H.M., Am. J. Oph-
thalmol., 104, 255 (1987)], herpes [Leibowitz, H.M.,
Corneal Disorders: Clinical Diagnosis and Management (W.B.
Saunders, Philadelphia, 1984], and other ailments from
donor to patient. Ih addition to these complications, many
patients with corneal disease or injury are not amenable to
transplantation. This can occur, for example, when there
is a chemical burn resulting in severe scarring and vascu-
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larization [Brightbill, F.S., Corneal Surgery: Theory,
Technique, and Tissue (Mosby-Year Book, St. Louis, 1993)].
To overcome these difficulties, alternatives to donor
tissue have been developed. One such alternative is a
prosthetic implant made of an optical cylinder and support-
ing flange [Polack, F.M. and Heimke, G., Ophthalmology, 87,
693 (1980); Trinkaus-Randall, V., Banwatt, R., Capecchi,
J., Leibowitz, H.M., and Franzblau, C., Invest. Ophthalmol.
vis. sci., 32, 3245 (1991)]. For post-operative stability,
implant materials must be biocompatible and promote cell
adhesion. When these two specifications are met, good
vision can be retained for 7 to 8 years after implantation.
Permanent stability, however, has yet to be obtained. In
refractive keratoplasty procedures, a synthetic intracor-
neal lens can be implanted to change the refractive power
of the cornea [McCarey, B.E., Refract. Corneal Surg., 6, 40
(1990); Insler, M.S., Boutros, G., and Caldwell, D.R., Am.
Intra-Ocular Implant Soc. J., Ii, 159 (1985)]. As before,
biocompatibility and cell adhesion are required for implan-
tation to be successful, but another requirement is perme-
ability so that nutrients can flow across the lens to the
anterior portion of the cornea. Synthetic lenses have been
stable in animal models for almost a decade. Clinical
trials are in an early stage.
The invention described in this patent application is
another alternative to the use of donor tissue for trans-
plantation. It can be used to prepare corneal tissue from
in vitro cultures of the patient's own corneal cells or
from a well-defined primary culture derived from another
human source. With in vitro produced tissue, shortage of
tissue and disease transfer to the patient would be mini-
mized. Also, post-operative stability should be greatly
enhanced with artificially generated tissue over that
currently obtained with a prosthesis or synthetic intra-
corneal lens.
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Reported corneal tissue regeneration has been limited
to date to two-dimensional models. In particular, regener-
ated corneal endothelial cells have been successfully
transplanted into animal models [Insler, M.S., and Lopez,
J.G., Curr. Eye Res., 5, 967 (1986)]. Since the endotheli-
um consists of a single layer of cells in the cornea, a
two'dimensional culture can be used for transplantation.
Since both the corneal epithelium and stroma are composed
of multiple layers of cells, three-dimensional tissue is
required to replace these cell structures when they become
damaged.
To study cell structure and function in normal and
abnormal cornea, three types of tissue models are currently
employed: intact tissue in living animals [Trinkaus-Ran-
dall, V., Banwatt, R., Capecchi, J., Leibowitz, H.M., and
Franzbla_, C., Invest. Ophthalmol. Vis. sci., 32, 3245
(1991)], donor tissue [Komai, Y. and Ushiki, T. Invest.
Ophthalmol. Vis. Sci., 32, 2244 (1991)], and tissue from in
vitro cell culture [Geroski, D.H. and Hadley, A., Curr. Eye
Res., ii, 61 (1992)]. The demand for these models is
increasing yearly. The number of donor eyes that were used
for research and education grew from 34,147 in 1989 to
40,239 in 1991 [Eye Bank Association of America, Annual
Report (Washington, D.C., 1992)]. In vitro cell culture
has certain advantages over the other two models: its use
avoids unnecessary loss of sight in lab animals and avoids
variation in tissue characteristic of corneas from differ-
ent donors. To date, the majority of cell-culture models
have been two-dimensional. These models are limited in
their applications, however, in that they preclude an
accurate representation of three-dimensional phenomena
within the cornea such as wound healing and mass transport
of nutrients from the endothelium to the stroma and to the
epithelium. For these phenomena, a three-dimensional model
is required. Furthermore, the synergistic interaction
7
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between different cell types in a three-dimensional model
could more accurately reflect the cell function in vivo
than a two-dimensional model.
The use of conventional stirred or sparged bioreactors
have not been generally successful for culture of three
dimensional, functional tissue. Some tissues such as the
Chinese hamster ovary cells grow robustly in conventional
stirred bioreactors [O'Connor, K.C. and Papoutsakis, E.T.,
Biotechnol. Tech., 6, 323 (1992)]. In contrast Sf9 fall
armyworm ovary cells will not grow at all in these reactors
under the same operating conditions; in fact, they die
unless supplemented with a liquid surfactant [Murhammer,
D.W. and Goochee, C.F., Biotechnol. Prog., 6, 391 (1990)].
Only limited work has been done to date to develop three-
dimensional corneal models. Bioreactors have not been used
for optic tissue growth such as cornea tissue. For exam-
ple, a model of multiple layers of rabbit corneal epitheli-
al cells grown on a support of contracted collagen lattices
was employed to investigate wound healing [Ouyang, P. and
Sugrue, S.P., "Identification of an Epithelial Protein
Related to the Desmosome and Intermediate Filment Network,"
J. Cell Biol., Vol. 118, pages 1477 - 1488, 1992] rather
than bioreactor produced cells.
A variety of different cells and tissues, such as bone
marrow, skin, liver, pancreas, mucosal epithelium, adeno-
carcinoma and melanoma, have been grown in culture systems
to provide three dimensional growth in the presence of a
pre-established stromal support matrix. U.S. Patent No.
4,963,489, Three-Dimensional Cell and Tissue Culture
System, Naughton, et al., October 16, 1990; U.S. Patent No.
5,032,508, Three-Dimensional Cell and Tissue Culture
System, Naughton, et% al., July 16, 1991. A biocompatible,
non-living material formed into a three dimensional struc-
ture is inoculated with stromal cells. In some cases, the
three dimensional structure is a mesh pre-coated with
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collagen. Stromal cells and the associated connective
tissue proteins naturally secreted by the stromal cells
attach to and envelop the three dimensional structure. The
interstitial spaces of the structure become bridged by the
stromal cells, which are grown to at least subconfluence
prior to inoculating the three dimensional stromal matrix
with tissue-specific cells. The cells are grown on an
artificial architecture rather than allowing for establish-
ing natural organization with dimensional segregation.
The invention described herein more closely approxi-
mates intact corneal tissue than other in vitro models
currently available. In the Sugrue model described above,
the contracted collagen lattices serve as a synthetic
extracellular matrix to which corneal cells can attached.
Because these lattices do not form the intricate structure
of the native matrix within corneal tissue, the Sugrue
model precludes the formation of cell structures character-
istic of native corneal tissue and, thus, precludes the
formation of transparent tissue. In the model described in
this invention, the internal structure of the tissue is
more akin to native cornea. Specifically, the tissue grown
on extracellular matrix synthesized by the cells them-
selves. There is also evidence of special organization of
the matrix and cells as well as dimensional segregation in
the tissue.
3O
SUMMARY OF THE INVENTION
Aggregates of optic tissue exemplified by cornea
tissue have been produced in vitro. The cell aggregates
form tissue by three dimensional cell growth. The cells
grow and multiply without artificial architecture as shown
in prior culture systems. The cells are functional and
exhibit the characteristics of normal cells in the three
dimensional growth and the formation of extracellular
matrix. The extracellular matrix is produced by the
9
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functional interrelationship of cell to cell contact. As
the artificially produced cell aggregates grow they form
their own natural structure, organization and architecture
without an artificial structure. The artificial architec-
ture or structure of the prior culture systems, such as
collagen lattices, prevent normal three-dimensional tissue
formation including extracellular matrix forlaation. The
cell aggregates of the present form the artificial tissue
more nearly shown with organized dimensional segregation.
The cells differentiate and grow along dimensional bound-
aries that are characteristic of the normal functional
tissue. Differentiation leads to segregation of cell
types. Cell function can be confirmed by immunocytochemis-
try with antibodies specific to particular components
produced by the cell types.
The artificially produced optic cell aggregates and
tissue were produced under low shear conditions. The low
shear conditions are contrasted to stirred or sparged
bioreators that attempt to suspend cells in culture media,
but produce such forces that cells such as optic cells
would die. Low shear is preferably created by using a
cylindrical culture vessel that rotates about its central
horizontal axis and contains suitable culture media.
During culture the horizontal rotation is modulated to
create low shear conditions providing the environment for
three dimensional cell growth. A cell attachment means is
provided in the culture vessel so that there is cell to
cell contact sufficient for growth which can be other cells
or a microcarrier. The microcarrier may be dissolvable and
as the cultured cells grow the microcarrier dissolves
completely away leaving only the tissue mass.
The bioreactors-preferred for use in this process are
referenced and incorporated into this disclosure. In the
preferred culture process the vessel is rotated to create
low shear at a low speed so that the circular motion of the
i0
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culture media minimizes centrifugal forces sufficient to
move cells outwardly from the rotational axis yet suspends
the cells throughout the vessel during culture. The
preferred cells are cornea and mammalian optic cells. A
further preferred cell inoculum is a mixed population of
primary corneal cells containing endothelial cells, epithe-
lial and keratocytes.
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DESCRIPTION OF THE DRAWINGS
Figure i. Negative control of corneal tissue at 200X
magnification for the immunocytochemistry study. This
control was prepared in the absence of primary antibody.
The photograph shows the extensive, multi-layer growth of
corneal cells in the HARV after 50 days of cultivation.
F_gure 2. Immunocytochemical characterization of
corneal tissue at 200X magnification. The intense brown
color relative to the negative control in Figure 1 indi-
cates that the tissue has stained strongly positive for
vimentin, a protein that is present in keratocytes (a type
of fibroblast) and endothelial cells.
Fiqure 3. Cell-bead aggregates at 200X magnification
in which corneal cells have bridged between microcarrier
beads. The tissue has stained strongly positive for
chondroitin-4-sulfate.
F_gure 4. Corneal tissue at 200X magnification that
has stained positive for chondroitin-6-sulfate. Staining
demonstrates that chondroitin has organized into layers
that are fairly parallel to each other.
Figure 5. Tissue growth around a microcarrier bead at
200X magnification. The cells have stained strongly
positive for fibronectin at the bead surface and more
moderately throughout the tissue.
ii
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DETAILED DESCRIPTION OF THE INVENTION
Three-dimensional corneal tissue has been produced
from an in vitro culture of primary rabbit corneal cells to
illustrate the production of optic cells from aggregates
and tissue. This tissue is a three-dimensional spheroid
that more closely approximates intact corneal tissue in
size and in morphology than has yet been achieved in vitro.
To generate the tissue, corneal cells were cultured in a
bioreactor called the High Aspect Ratio Vessel (HARV)
described in the published patent application by the
National Aeronautics and Space Administration in the
Scientific and Technical Aerospace Reports Volume 29/Number
9, May 8, 1991, ACC NOS. N91-17531, U.S. Serial No.
625,345, now U.S. Patent No. 5,153,131, entitled "A Culture
Vessel With Large Perfusion Area to Volume Ratio," invented
by David A. Wolf, Clarence F. Sams and Ray P. Schwarz and
filed on December II, 1990 and issued October 6, 1992,
previously incorporated by reference.
The corneal tissue described herein is unique and the
HARV produced tissue has distinctive features. Corneal
tissue is one of the most dependent on the formation of
three-dimensional extracellular matrices. As discussed
herein, these matrices are responsible for the intricate
order of cell layers in the cornea and, in turn, are
responsible for its transparency and focusing power. This
invention demonstrates that these matrices form and provide
an internal structure to corneal tissue. This invention
demonstrates that the HARV supports robust grown of corneal
cultures.
The corneal tissue produced in the HARV was initiated
from a mixed population of primary corneal cells (BioWhit-
taker, Walkersville_ MD) containing endothelial cells,
epithelial cells and keratocytes. These cells are attach-
ment dependent and, as such, were grown bound to a support,
Cytodex-3 microcarrier beads (Pharmacia, Piscataway, NJ).
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To prepare the beads for culture, they were first hydrated
in Ca 2+, Mg 2+ free phosphate buffer saline (PBS) for 3 hours
with occasional gentle agitation at room temperature and a
concentration of 50-100ml/g bead. The beads were subse-
quently washed with fresh (30-50 ml/g bead) and sterilized
at I15°C and 15 psi for 15 minutes in PBS at the same
concentration. Before initiating a microcarrier culture,
the PBS was washed from the sterile beads by rinsing in
ward culture medium.
Alternative attachment means may be used such as
dissolvable microcarriers. Also other cells introduced
into the culture may be an attachment means so that the
cells use each other as support.
Corneal cultures were grown in two types of vessels:
the }LARV and a Bellco spinner flask (Vineland, NJ). The
latter vessel served as a control with which to compare the
HARV. The spinner flask is the conventional vessel of
choice for the preparation of the microcarrier cell cul-
tures. In both vessels, cultures were inoculated with 1 x
105 viable cells/ml and a bead density of 5 mg/ml in 50 ml
GTSF-2 medium (NASA, Houston, TX) containing 5% (v/v) fetal
bovine serum. During cultivation, the vessels were main-
tained at pH 7.4, 37 ° C, 5% CO 2 and 95% relative humidity.
Corneal cells were fed according to glucose consumption,
maintaining a level of 40-80 mg/dl glucose.
Prior to inoculation, spinner flasks were siliconized
with Sigmacote (Sigma, St. Louis, MO) to prevent cell
adhesion to the flask walls. Corneal cells were maintained
in suspension in the spinner flask by impeller mixing at 60
rpm. These cultures reached stationary phase within one
wee]< of inoculation. At that time, cells had attached to
the microcarrier beads, but there was minimal aggregation
of beads. As a result, no tissue formed in the shaker
flask.
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For HARV cultivation, cells were suspended in culture
medium by end-over-end rotation of the vessel at 11-25 rpm.
The vessel was completely filled with medium, eliminating
cell damage from hydrodynamic forces associated with
air/liquid interfaces and boundary layer at the vessel
wall. The HARVhas three ports for medium replacement and
sampling. Replacing medium in HARV required stopping
vessel rotation, allowing the cells to settle, and removing
20% of the spent medium through the top port. Fresh medium
was then injected under sterile conditions with a syringe.
Within 24 hours of inoculation, cells attached to the
microcarrier beads. After an additional week, cell/bead
aggregates developed as cells bridged between beads as
shown in Figure 3. These aggregates grew in size to form
tissue in the HARV over 2.5 months.
The concentration of cells present in either vessel
was measured by counting released nuclei. Specifically,
aggregated corneal tissue was exposed to 25 _g/ml collage-
nase type IA (Sigma) in Ca2+, Mg2+-free PBS containing 0.02%
(w/v) ethylenediaminetetraacetic acid at 37 ° C to release
cell nuclei. Next, the nuclei were stained with 0.1% (w/v)
crystal violet in 0.i M citric acid (Sigma) and counted
with a hemocytometer.
The tissue produced in the HARV from corneal cells is
a three-dimensional spheroid greater than 5 mm in diameter
containing multiple layers of cells as shown in Figure i.
The maximum cell density that was achieved in the HARV was
in excess of 1 x 107 cells/ml. In contrast, the corneal
cells grew for only a period of a week in the spinner
flask, reaching a maximum cell density of only 4.5 x 105
cells/ml. As mentioned above, aggregation in the spinner
flask, reaching a maximum cell density of only 4.5 x 105
cells/ml. As mentioned above, aggregation in the spinner
flask was not substantial; on average, aggregates were 1 mm
in diameter or less. Spinner flasks maintain cells in
14
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suspension through impeller mixing. This design generates
turbulent eddies in the grown medium which cause cell-cell
collisions that disrupt aggregates, inhibiting three-
dimensional cell growth [Cherry, R.S. and Papoutsakis, E.T.
Bioprocess Eng., I, 29 (1986)].
Immunocytochemistry was used to characterize the
composition and internal organization of artificially
produced corneal tissue. For this analysis, tissue sam-
ples, each 1.0 ml in volume, were removed from the HARV
after 50 days of cultivation. They were washed with PBS
and then fixed in 1.0 ml of OmniFix II (An-Con Genetics,
Melville, NY), an alcohol-based fixative not containing
aldehydes or mercury. Samples were paraffin embedded,
blocked, sectioned and mounted on slides using standard
methodology. After the mounted sections were deparaf-
finized and rehydrated, they were exposed to a primary
mouse antibody directed against specific proteins expressed
in the tissue as shown below in Table I. This was followed
by exposure to a secondary antibody, peroxidase-labeled,
anti-mouse antibody (Boehringer Mannheim, Indianapolis,
IN), which binds to the primary antibody. To visualize
antibody binding, sections were incubated with diaminoben-
zidine (Sigma) solubilized in a solution of Tris buffer and
H202 . Diaminobenzidine reacts with peroxidase to form a
brown color.
15
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TABLE 1
PRIMARY ANTIBODIES USED FOR IMMUNOCYTOCHEMICAL
ANALYSIS
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Antibody
Specificity
Vimentin
Chondroitin-4-
Sulfate
Chondroitin-6-
Sulfate
Fibronectin
Dilution
1:20
1:75
1:50
1:40
Source, Location
& Order No.
Boehringer Mannheim,
Indianapolis, IN
1112457
Chemicon, Temecula, CA
MAB2030
Chemicon, MAB2035
Boehringer Mannheim,
1087720
Analysis by immunocytochemistry revealed substantial
extraceliular matrix expression in the corneal tissue. Of
the two classes of macromolecules that constitute the
matrix, glycosaminoglycans' (GAG's) and fibrous proteins,
both were present in the tissue.
The brown color in Figures 3 and 4 relative to the
negative control in Figure 1 shows expression of the GAG's
chondroitin-4- and -6- sulfate. These two macromolecules
are sulfated disaccharides that differ from each other in
the position of their sulfate residue. Chondroitin-4-
sulfate is sulfated at the C4 position of N-acetyl-D
galactosamine, while chondroitin-6-sulfate is sulfated at
the C6 position. In Figure 3, stained for chondroitin-4-
sulfate, the microcarrier beads are shown at i0, 12 and 14.
The tissue between the beads, for example at 16 and 18,
shows the strong staining for matrix component chondroitin-
4-sulfate. In Figure 4, stained for chondroitin-6-sulfate,
the tissue shows layers of cells with organized dimensional
segregation. The layers of cells appear as waves of cells
with staining.
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As for fibrous proteins, fibronectin staining is
depicted in Figure 5. The darker stain as illustrated at
reference numerals 20 and 22 is at the bead surface 24.
This concentration of fibronectin at the cell bead inter-
face is evidence of matrix organization and promotes cell
adhesion to the bead surface.
These figures also reveal three-dimensional organiza-
tion and segregation of these matrix macromolecules within
the artificially produced tissue. In particular, Figure 4
demonstrates that chondroitin-6-sulfate organized into
parallel layers that were separated from each other by 10_m
on average. While Figure 5 indicates that fibronectin was
moderately expressed through the corneal tissue, it also
shows that this protein concentrated at the cell/bead
interface to promote cell adhesion to the bead surface.
Matrix formation permitted cell types within the
regenerated tissue to organize and segregate. The cells
migrated along the matrix to form distinct clusters of
individual cell types. This is evident in Figure 2.
Recall that tissue was prepared from a mixed population of
endothelial cells, epithelial cells and keratocytes.
Figure 2 shows strong positive staining for vimentin. This
protein is an intermediate filament present in keratocytes
and endothelial cells. The dense foci of brown color as
shown at reference numerals 2, 4, 6, 8 and elsewhere in the
figure depict distinct clusters that these cell types form
in vivo. This shows that the cells have organized within
the tissue.
The invention of three-dimensional corneal tissue,
produced from in vitro cell culture and described herein,
is closer in size and in morphology to intact corneal
tissue than earlier _ttempts at in vitro production. This
novel three-dimensional tissue can be used to model cell
structure and function in normal and abnormal cornea.
Also, it can eventually be used to develop tissue for
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patients requiring corneal transplantations. This process
may also be used for non-mammalian optic and cornea tissue
production for study and use with other animal forms.
The description of the process and embodiment is
illustrative of the invention and is not intended to place
any limitation on the claims of invention. Those skilled
in the art will recognize other modes of practicing the
invention described herein.
18
PATENT
5
ABSTRACT
A process for artificially producing three-dimensional
optic tissue has been developed. The optic cells are
cultured in a bioreactor at low shear conditions. The
tissue forms as normal, functional tissue grows with tissue
organization and extracellular matrix formation.
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